UKALL14. Non-Myeloablative Conditioning Regimen (1/1) Date started (dd/mm/yyyy) (Day 7) Weight (kg) BSA (m 2 )

Similar documents
Rob Wynn RMCH & University of Manchester, UK. HCT in Children

3.1 Clinical safety of chimeric or humanized anti-cd25 (ch/anti-cd25)

Reduced-intensity Conditioning Transplantation

Experience of patients transplanted with naïve T cell depleted stem cell graft in CMUH

MUD HSCT as first line Treatment in Idiopathic SAA. Dr Sujith Samarasinghe Great Ormond Street Hospital for Children, London, UK

What s a Transplant? What s not?

5/9/2018. Bone marrow failure diseases (aplastic anemia) can be cured by providing a source of new marrow

An Overview of Blood and Marrow Transplantation

Haploidentical Transplantation: The Answer to our Donor Problems? Mary M. Horowitz, MD, MS CIBMTR, Medical College of Wisconsin January 2017

Neutrophil Recovery: The. Posttransplant Recovery. Bus11_1.ppt

Acknowledgements. Department of Hematological Malignancy and Cellular Therapy, University of Kansas Medical Center

HSCT - Minimum Essential Data - A FOLLOW UP REPORT - ANNUAL

Revista Cubana de Hematología, Inmunología y Hemoterapia. 2017; 36 (Suplemento).

One Day BMT Course by Thai Society of Hematology. Management of Graft Failure and Relapsed Diseases

The question is not whether or not to deplete T-cells, but how to deplete which T-cells

Feasibility and Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in 30 Patients with Poor Risk Acute Myeloid Leukemia Older than 60 Years

Treatment of Chronic Graft versus Host Disease. Daniel Weisdorf MD University of Minnesota

EBMT Complications and Quality of Life Working Party Educational Course

Treatment of Thrombocytopenia After Allogeneic Hematopoietic Stem Cell Transplantation with Eltrombopag

Trends in Hematopoietic Cell Transplantation. AAMAC Patient Education Day Oct 2014

Complications after HSCT. ICU Fellowship Training Radboudumc

T-CELL DEPLETION: ALEMTUZUMAB IN THE BAG

New Evidence reports on presentations given at EHA/ICML Bendamustine in the Treatment of Lymphoproliferative Disorders

Introduction to Clinical Hematopoietic Cell Transplantation (HCT) George Chen, MD Thursday, May 03, 2018

Non-infectious hepatic complications in patients with GVHD

ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOBLASTIC LEUKEMIAS

Federica Galaverna, 1 Daria Pagliara, 1 Deepa Manwani, 2 Rajni Agarwal-Hashmi, 3 Melissa Aldinger, 4 Franco Locatelli 1

HLA-DR-matched Parental Donors for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with High-risk Acute Leukemia

UMBILICAL CORD BLOOD STEM CELLS EXPANDED IN THE PRESENCE OF NICOTINAMIDE (NICORD) PROVIDE LONG TERM MULITI-LINEAGE ENGRAFTMENT

UNRELATED DONOR TRANSPLANTATION FOR SICKLE CELL DISEASE AN UPDATE

Lung Injury after HCT

Overview of New Approaches to Immunosuppression in Renal Transplantation

Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT

Reduced Intensity Conditioning (RIC) Allogeneic Stem Cell Transplantation for LLM: Hype, Reality or Time for a Rethink

HSCT - Minimum Essential Data - A REGISTRATION - DAY 0

Nothing to disclose. Title of the presentation - Author

The future of HSCT. John Barrett, MD, NHBLI, NIH Bethesda MD

UKALL14. A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia

Post Transplant Management for Sickle Cell. Title

Allogeneic Hematopoietic Stem Cell Transplantation: State of the Art in 2018 RICHARD W. CHILDS M.D. BETHESDA MD

Corporate Medical Policy

Dedicated to Gordon. Stem Cell Transplantation: The Journey

Objectives. What is Aplastic Anemia. SAA 101: An Introductory Course to Severe Aplastic Anemia

KTE-C19 for relapsed or refractory mantle cell lymphoma

Haploidentical Transplants for Lymphoma. Andrea Bacigalupo Universita Cattolica Policlinico Gemelli Roma - Italy

Haploidentical Stem Cell Transplantation with post transplantation Cyclophosphamide for the treatment of Fanconi Anemia

Acute GVHD. ESH-EBMT 2009 Latimer A. Devergie

HSCT - Minimum Essential Data - A REGISTRATION - DAY 0

THE ROLE OF TBI IN STEM CELL TRANSPLANTATION. Dr. Biju George Professor Department of Haematology CMC Vellore

Haploidentical Transplantation today: and the alternatives

London, 27 October 2005 Product Name: Busilvex Procedure no.: EMEA/H/C/472/II/0004 SCIENTIFIC DISCUSSION

Cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Company Presentation June 2016

Clinical Commissioning Policy Proposition: Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation

PUO in the Immunocompromised Host: CMV and beyond

Haplo vs Cord vs URD Debate

MATCHMAKER, MATCHMAKER, MAKE ME A MATCH, FIND ME A MISMATCHED TRANSPLANT TO CATCH

Instructions for Chronic Lymphocytic Leukemia Post-HSCT Data (Form 2113)

Clinical Policy: Donor Lymphocyte Infusion

High-Dose Carmustine, Etoposide, and Cyclophosphamide Followed by Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma

4100: Cellular Therapy Essential Data Follow-Up Form

HSCT - Minimum Essential Data - A REGISTRATION - DAY 0

Review Article Haploidentical Stem Cell Transplantation in Adult Haematological Malignancies

Outcomes of Transplantation with Related- and Unrelated-Donor Stem Cells in Children with Severe Thalassemia

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 18 July 2012

Transition from active to palliative care EBMT, Geneva, Dr. med. Gayathri Nair Division of Hematology

KT Godder, J Metha, KY Chiang, S Adams, F van Rhee, S Singhal, K Higgins-Smith, W O Neal, S DeRienzo and JP Henslee-Downey.

Summary of Changes Page BMT CTN 1205 Protocol Amendment #4 (Version 5.0) Dated July 22, 2016

Related haploidentical donors versus matched unrelated donors

The National Marrow Donor Program. Graft Sources for Hematopoietic Cell Transplantation. Simon Bostic, URD Transplant Recipient

Non-Myeloablative Transplantation

Tolerance Induction in Transplantation

Transplantation Immunology

Transplantation Immunology

Setting The setting was secondary care. The economic analysis was carried out in Canada.

TRANSPARENCY COMMITTEE OPINION. 8 November 2006

NiCord Single Unit Expanded Umbilical Cord Blood Transplantation: Results of Phase I/II Trials

UKALL14. A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia. Protocol version & date: Version

Supplemental Table 1 Multivariate analysis of neutrophil and platelet

Hematopoietic Stem Cell Transplant in Sickle Cell Disease- An update

Rituximab, and autologous stem cell collection rate after induction therapy with Bortezomib-Rituximab. 4 Not yet recruiting

An Introduction to Bone Marrow Transplant

A.M.W. van Marion. H.M. Lokhorst. N.W.C.J. van de Donk. J.G. van den Tweel. Histopathology 2002, 41 (suppl 2):77-92 (modified)

HSCT - Minimum Essential Data - A REGISTRATION - DAY 0

Introduction: Trial contacts: Trial Management Group (TMG):

Comparison of Reduced-Intensity and Conventional Myeloablative Regimens for Allogeneic Transplantation in Non-Hodgkin s Lymphoma

Low-Dose Total Body Irradiation, Fludarabine, and Antithymocyte Globulin Conditioning for Nonmyeloablative Allogeneic Transplantation

Umbilical Cord Blood Transplantation

HSCT - Minimum Essential Data - A REGISTRATION - DAY 0

Busulfan/Cyclophosphamide (BuCy) versus Busulfan/Fludarabine (BuFlu) Conditioning Regimen Debate

Stem cell transplantation for haemoglobinopathies. Dr P J Darbyshire Birmingham Childrens Hospital

How I manage patients with complex GI problems. Mark Williams ST5 Haematology Manchester Royal Infirmary

Modulating STAT Signaling to Promote Engraftment of Allogeneic Bone Marrow Transplant

Disclosure. Objectives 1/22/2015

UPDATE Autologous Stem Cell Transplantation for Lymphoma and Myeloma

MUD SCT. Pimjai Niparuck Division of Hematology, Department of Medicine Ramathibodi Hospital, Mahidol University

PBMC from each patient were suspended in AIM V medium (Life Technologies) with 5%

Allogeneic Stem Cell Transplantation for Cutaneous T-cell Lymphoma: Updated results from a single center

Donor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant

Transcription:

Non-Myeloablative Conditioning Regimen (1/1) started (dd/mm/yyyy) (Day 7) BSA (m 2 ) Weight (kg) Please enter the daily dose given in the table below: Day Fludarabine (mg) Melphalan (mg) Alemtuzumab (mg) -7-6 -5-4 -3-2 -1

Myeloablative Conditioning Regimen (1/2) myeloablative conditioning started (dd/mm/yyyy) (Day 7) BSA (m 2 ) Weight (kg) Please enter the daily dose given in the table below: Day Etoposide (mg) Cyclophosphamide (mg) Fractionated TBI (daily dose) (cgy) -7-6 -5 OR -4-3 -2-1

Myeloablative Conditioning Regimen (2/2) GvHD Prevention Did the patient receive Methotrexate for GvHD prevention? (1=Yes, 2=No) Drug No of doses given Methotrexate T-cell depletion Was T-cell depletion considered necessary? (1=Yes, 2=No) If yes, was T-cell depletion given as recommended in the protocol? (1=Yes, 2=No) If No, please complete the table below. Please specify the day of the conditioning regimen (e.g Day 2) and the dose given) Day Alemtuzumab (mg)

Palifermin Form (1/1) Myeloablative Conditioning Regimen - Palifermin Randomisation: Randomisation s 40 years of age being treated with the Myeloablative Conditioning regimen. started (dd/mm/yyyy) (Day 10) Key: Dose of Palifermin: P1 = Standard P2 = Collapsed Weight (kg) finished (dd/mm/yyyy) (Day 4) Please enter the daily dose given in the table below, and indicate any reduction/delay/ omission. Day -10-9 -8 0 2 4 Palifermin (µg) Reduction 1 Delay 1 Omission 1 1 0=No reduction/delay/omission, 1=Neurotoxicity, 2=Hepatotoxicity, 3=Cardiotoxicity 4=Haematological Toxicity 5=Infusion-related toxicity 6=Pancreatitis 7= Choice, 8=Clinician Choice, 9=Administrative, 10=Other (specify below): Day 10 = OTHER Reason for Reduction/Delay/Omission -10-9 -8 0 2 4

Oral Daily Mucositis Questionnaire (1/1) ODMQ To be completed daily by all patients receiving a myeloablative transplant, during in-patient therapy from day -12 until day 28 or date of discharge (whichever is sooner) of Assessment (dd/mm/yyyy)

Transplant Form (1/1) Haematopoietic Stem Cell Transplant Transplant date Source of stem cells Source of stem cells (1=peripheral blood, 2=bone marrow, 3=peripheral blood and bone marrow, 4=cord blood) Please complete the total of cells infused for the source of stem cells given above: Peripheral Blood CD34+ (cells/kg) AND/OR Bone Marrow CD34+ (cells/kg) Donor details Type of donor (1=sibling, 2=8/8 MUD, 3=7/8 MMUD, 4=cord blood) Donor sex (1=male, 2=female) Donor CMV status (1=positive 2=negative)

Day 100 Form (1/2) Transplant Outcome Day 100 (dd/mm/yyyy) Remission Status Remission Status (1=Complete remission 2=Not in remission) If not in remission, please complete a relapse form. Graft versus Host Disease Has the patient experienced GvHD post transplant? (1=Yes, 2=No) If yes above, please complete a GvHD form. Engraftment Neutrophil count of 0.5 x 10 9 /L reached? (1=Yes, 2=No, 3=Never below this level) If Yes, please specify the date: Neutrophil count reached 0.5 x 10 9 /L (first of 3 consecutive days) IF NO, PLEASE COMPLETE A GRAFT FAILURE FORM Platelet count of 20 x 10 9 /L reached? (1=Yes, 2=No, 3=Never below this level) If Yes, please specify the date: platelet count reached 20 x 10 9 /L (first of 3 consecutive days) IF NO, PLEASE COMPLETE A GRAFT FAILURE FORM Infection Radiological evidence of pneumonia (1=Yes, 2=No) Please document any infections that occurred during Transplant Treatment on the AE form

Day 100 Form (2/2) Other Complications of Transplant Did the patient experience any of the complications listed below during inpatient stay (1=Yes, 2=No) If Yes, please specify which complication below:(1=yes, 2=No) Veno-occlusive disease (VOD) Diffuse Alveolar Damage (DAD) Creatinine >200 Was dialysis required? (1=Yes, 2=No) Was ITU admission required? (1=*Yes, 2=No) If yes, was this EXEMPT from SAE reporting? (1=Yes, 2=No) (*See SAE reporting time frames, exemptions and flowchart in protocol section 12.2.2) If NO, an SAE report is required Please document any other non infection related complications that occurred during Transplant Treatment on the AE form Discharge Has the patient been discharged from hospital? (1=Y, 2=N) If yes above, please complete the date of discharge below of discharge

GvHD Form (1/2) GvHD Assessment This form should be completed for each separate episode of GvHD that the patient experiences. The form should be updated as necessary until the episode resolves. (please initial and date any changes). Report separate episodes on a new form. of onset of this episode of GvHD (dd/mm/yyyy) Has this episode of GvHD resolved? (1=Yes, 2=No) If yes, of resolution of this episode of GvHD: GvHD Assessment Please indicate the type of GvHD 1=Acute GvHD within 100 days of transplant, 2=Acute GvHD > 100 days due to DLI, 3=Chronic GvHD > 100 days after transplant, 4=Chronic GvHD arising from Acute GvHD Please complete either the Acute or Chronic section below and the treatment section overleaf Acute GvHD Stage: Skin (0-4) Liver (0-4) Gut (0-4) Maximum Grade Chronic GvHD Grade 1=limited, 2=extensive Platelet count less than 100 x 10 9 /L 1=Yes, 2=No Organs Affected Skin (0=not affected, 1=localised, 2=generalised) Liver (0=not affected, 1=general dysfunction, 2=histology showing chronic aggressive hepatitis/bridging necrosis /cirrhosis) Lungs (0=not affected, 1=Bronchiolitis obliterans) Gut (0=not affected, Mouth (0=not affected, Eyes 1=affected) 1=affected) (0=not affected, 1=affected) Genitourinary (0=not affected, 1=affected) Other (0=not affected, 1=affected)

GvHD Form (2/2) GvHD Assessment Treatment for GvHD Please specify the treatment given below:(1=yes, 2=No) Topical therapy (including topical steroids) Calcineurin inhibitors Systemic Steroids Pentostatin Thalidomide Rituximab ECP MMF Other monoclonal antibody Other (specify)

Graft Failure Form (1/1) Graft Failure graft failure confirmed (dd/mm/yyyy) of days post transplant Please indicate the type of graft failure (1=Primary, 2=Secondary) PRIMARY GRAFT FAILURE Day 28 Neutrophil count X 10 9 /L Most recently recorded % donor chimerism: % PMBC % T-cell % Granulocyte SECONDARY GRAFT FAILURE primary engraftment achieved (dd/mm/yyyy) secondary graft failure recorded (dd/mm/yyyy) Neutrophil count at secondary graft failure X 10 9 /L % donor chimerism when secondary graft failure recorded: % PMBC % T cell % Granulocyte

Post Transplant Assessment Form (1/1) of Assessment (dd/mm/yyyy) Assessment Month 6/9/12/15/18/21/24 Months post transplant Discharge Please only complete for patients who had not been discharged from hospital by Day 100. Has the patient been discharged from hospital? (1=Yes, 2=No) If Yes, please complete date below of discharge status Please indicate patient status (1=Alive 2=Dead) Has the patient relapsed? (1=Yes, 2=No) Has the patient been diagnosed with a second cancer (1=Yes, 2=No) Please ensure the relevant Death, Relapse or Second Cancer Form is also completed. Donor Lymphocyte Infusion Has the patient been given DLI? (1=Yes,2=No) If yes, please enter DLI details below: of DLI doses given? DLI given (dd/mm/yyyy) CD3 dose/kg Reason for giving DLI (1=mixed chimerism 2=continued or progressive minimal residual disease 3=Both) Graft versus Host Disease Has the patient experienced GvHD since the last assessment? (1=Yes, 2=No) If yes, a new GvHD form should be completed for any new episodes of GvHD, ensuring any previous forms have been updated. If this episode of GvHD is ongoing from the last assessment, please ensure the current GvHD form is updated with any new information.